This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a
number of ascending doses administered for 14 days in healthy volunteers.
- males or females of non-childbearing capacity
- No medical, neurological or psychiatric illness
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Pfizer Clinical Trials Contact Center
call now email
Contact a representative by phone, email, or visiting the study website. Please see the references below: